Short Interest in MDxHealth SA (NASDAQ:MDXH) Declines By 24.2%

MDxHealth SA (NASDAQ:MDXH) was the target of a large decrease in short interest in February. As of February 27th, there was short interest totaling 17,033 shares, a decrease of 24.2% from the February 12th total of 22,470 shares. Based on an average daily volume of 112,233 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 112,233 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On MDxHealth

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kennedy Capital Management LLC purchased a new position in MDxHealth during the third quarter valued at $1,826,000. Marshall Wace LLP purchased a new stake in shares of MDxHealth during the fourth quarter worth about $609,000. Mink Brook Asset Management LLC purchased a new stake in shares of MDxHealth during the third quarter worth about $743,000. Panoramic Capital LLC acquired a new position in shares of MDxHealth during the 3rd quarter worth about $721,000. Finally, FreeGulliver LLC raised its position in shares of MDxHealth by 104.7% during the 3rd quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock worth $1,176,000 after purchasing an additional 129,348 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. BTIG Research reissued a “buy” rating and set a $7.00 price target on shares of MDxHealth in a report on Tuesday, December 23rd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.75.

MDxHealth Price Performance

NASDAQ MDXH traded up $0.17 during trading hours on Monday, reaching $3.37. The company’s stock had a trading volume of 67,343 shares, compared to its average volume of 124,333. The firm has a market capitalization of $166.80 million, a price-to-earnings ratio of -5.03 and a beta of 1.61. The company’s 50-day moving average is $3.52 and its two-hundred day moving average is $3.78. MDxHealth has a 1-year low of $1.36 and a 1-year high of $5.33.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings data on Thursday, February 26th. The company reported $999.00 EPS for the quarter, beating the consensus estimate of ($0.13) by $999.13. The company had revenue of $29.55 million for the quarter, compared to analyst estimates of $26.05 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 31.07%. Equities analysts forecast that MDxHealth will post -1.15 EPS for the current fiscal year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.